MF6 Stock Overview
Develops advanced nanomedicine for cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MagForce AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €3.50 |
| 52 Week Low | €0.11 |
| Beta | 1.53 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -96.30% |
| 33 Year Change | -97.41% |
| 5 Year Change | -98.45% |
| Change since IPO | -99.82% |
Recent News & Updates
Shareholder Returns
| MF6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -0.4% |
| 1Y | -96.3% | -7.1% | 7.1% |
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: MF6 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| MF6 volatility | |
|---|---|
| MF6 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MF6 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MF6's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 33 | Ben Lipps | www.magforce.de/ |
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of brain tumors; NanoPlan, a software that supports the attending physician in preparing the ideal treatment plan for the NanoTherm therapy; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG Fundamentals Summary
| MF6 fundamental statistics | |
|---|---|
| Market cap | €3.56m |
| Earnings (TTM) | -€10.57m |
| Revenue (TTM) | €1.08m |
3.3x
P/S Ratio-0.3x
P/E RatioIs MF6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MF6 income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €918.75k |
| Gross Profit | €158.39k |
| Other Expenses | €10.73m |
| Earnings | -€10.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 14.70% |
| Net Profit Margin | -981.70% |
| Debt/Equity Ratio | 95.5% |
How did MF6 perform over the long term?
See historical performance and comparison